PURPOSE OF REVIEW: Lymph node dissection (LND) during radical nephrectomy (RN) for renal cell carcinoma (RCC) is not considered as a standard. The emergence of robot-assisted surgery and effective immune checkpoint inhibitors (ICI) in recent years may change this and lymph node (LN) staging has become easier and has a clinical impact. In this review, we aimed to reconsider the role of LND today. RECENT FINDINGS: Although the extent of LND has still not been well established, removal of more LN seems to provide better oncologic outcomes for a select group of patients with high-risk factors such as clinical T3-4. Adjuvant therapy using pembrolizumab has been shown to improve disease free survival if complete resection of metastatic lesions as well as the primary site is obtained in combination. Robot assisted RN for localized RCC has been widespread and the studies regarding LND for RCC has been recently appeared. SUMMARY: The staging and surgical benefits and its extent of LND during RN for RCC remains unclear, but it is becoming increasingly important. Technologies that allow an easier LND and adjuvant ICI that improve survival in LN-positive patients are engaging the role of LND, a procedure that was needed, but almost never done, is now indicated sometimes. Now, the goal is to identify the clinical and molecular imaging tools that can help identify with sufficient accuracy who needs a LND and which LNs to remove in a targeted personalized approach.

Cancer Prognostic and Health Outcomes Unit Division of Urology University of Montreal Health Center Montreal Canada

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna

Department of Urology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University of Texas Southwestern Medical Center Dallas Texas

Department of Urology Weill Cornell Medical College New York New York USA

Division of Urology Department of Special Surgery The University of Jordan Amman Jordan

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Zobrazit více v PubMed

Bandini M, Smith A, Zaffuto E, et al. . Effect of pathological high-risk features on cancer-specific mortality in nonmetastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. World J Urol 2018; 36:51–57. PubMed

Marchioni M, Amparore D, Magli IA, et al. . Potential benefit of lymph node dissection during radical nephrectomy for kidney cancer: a review and critical analysis of current literature. Asian J Urol 2022; 9:215–226. PubMed PMC

Capitanio U, Montorsi F. Renal cancer. Lancet 2016; 387:894–906. PubMed

Blom JH, van Poppel H, Maréchal JM, et al. . Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55:28–34. PubMed

Campi R, Sessa F, Di Maida F, et al. . Templates of lymph node dissection for renal cell carcinoma: a systematic review of the literature. Front Surg 2018; 5:1–11. PubMed PMC

Nini A, Larcher A, Cianflone F, et al. . The effect of anatomical location of lymph node metastases on cancer specific survival in patients with clear cell renal cell carcinoma. Front Surg 2018; 5:1–8. PubMed PMC

Shi X, Feng D, Li D, et al. . The role of lymph node dissection for nonmetastatic renal cell carcinoma: an updated systematic review and meta-analysis. Front Oncol 2021; 11:1–11. PubMed PMC

Marchioni M, Bandini M, Pompe RS, et al. . The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT(2-3) nonmetastatic renal cell carcinoma treated with radical nephrectomy. BJU Int 2018; 121:383–392. PubMed

Kates M, Lavery HJ, Brajtbord J, et al. . Decreasing rates of lymph node dissection during radical nephrectomy for renal cell carcinoma. Ann Surg Oncol 2012; 19:2693–2699. PubMed

Capitanio U, Stewart GD, Larcher A, et al. . European temporal trends in the use of lymph node dissection in patients with renal cancer. Eur J Surg Oncol 2017; 43:2184–2192. PubMed

Zhuang W, Chen J, Li Y, Liu W. Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software. Int Urol Nephrol 2020; 52:253–262. PubMed

Xiao R, Xu C, Ge L, et al. . Prognostic value of positive lymph nodes in patients with renal cell carcinoma and tumor thrombus undergoing nephrectomy and thrombectomy. Urol Int 2021; 105:657–665. PubMed

Powles T, Tomczak P, Park SH, et al. . Pembrolizumab versus placebo as postnephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23:1133–1144. PubMed

Kuusk T, Klatte T, Zondervan P, et al. . Outcome after resection of occult and nonoccult lymph node metastases at the time of nephrectomy. World J Urol 2021; 39:3377–3383. PubMed

Kuusk T, De Bruijn R, Brouwer OR, et al. . Lymphatic drainage from renal tumor in vivo: a prospective sentinel node study using CPECT/CT imaging. J Urol 2018; 199:1426–1432. PubMed

Capitanio U, Matloob R, Suardi N, et al. . The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma. Urologia 2012; 79:109–115. PubMed

Kwon T, Song C, Hong JH, et al. . Reassessment of renal cell carcinoma lymph node staging: analysis of patterns of progression. Urology 2011; 77:373–378. PubMed

Mehta V, Mudaliar K, Ghai R, et al. . Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat. Arch Pathol Lab Med 2013; 137:1584–1590. PubMed

Capitanio U, Suardi N, Matloob R, et al. . Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int 2014; 114:210–215. PubMed

Feuerstein MA, Kent M, Bazzi WM, et al. . Analysis of lymph node dissection in patients with ≥7-cm renal tumors. World J Urol 2014; 32:1531–1536. PubMed PMC

Kuusk T, Zondervan P, Lagerveld B, et al. . Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. Urol Oncol 2020; 38:521–525. PubMed

Tachibana I, Vasquez R, Mahmoud M, et al. . Can retroperitoneal lymph node dissection (RPLND) be feasibly performed to prolong survival in renal cell carcinoma (RCC) with limited lymph node involvement? an analysis of recurrence patterns. Urol Oncol 2022; 40:495.e11–495.e17. PubMed

Bacic J, Liu T, Thompson RH, et al. . Emulating target clinical trials of radical nephrectomy with or without lymph node dissection for renal cell carcinoma. Urology 2020; 140:98–106. PubMed PMC

Kokorovic A, Breau RH, Kapoor A, et al. . Lymph node dissection during radical nephrectomy: a Canadian multiinstitutional analysis. Urol Oncol 2021; 39:371.e17–371.e25. PubMed

Wei Y, Wang M, Jin Y, et al. . Extent of lymph node dissection improves overall survival in pT3N0 nonmetastatic renal cell carcinoma patients treated with radical nephrectomy: a propensity score-based analysis. World J Urol 2020; 38:1579–1585. PubMed

Laganosky D, Filson CP, Patil D, Master VA. Survival benefit with extended lymphadenectomy for advanced renal malignancy: a population-based analysis. Asian J Urol 2020; 7:29–36. PubMed PMC

Moschini M, Dell’Oglio P, Larcher A, Capitanio U. Lymph node dissection for renal cell carcinoma: what are we missing? Curr Opin Urol 2016; 26:424–431. PubMed

Gershman B, Moreira DM, Thompson RH, et al. . Perioperative morbidity of lymph node dissection for renal cell carcinoma: a propensity score-based analysis. Eur Urol 2018; 73:469–475. PubMed

Ristau BT, Manola J, Haas NB, et al. . Retroperitoneal lymphadenectomy for high risk, nonmetastatic renal cell carcinoma: an analysis of the ASSURE (ECOG-ACRIN 2805) adjuvant trial. J Urol 2018; 199:53–59. PubMed PMC

Gershman B, Thompson RH, Moreira, et al. . Lymph node disecction is not associated with improved survival among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma: a propensity score based analysis. J Urol 2017; 197:574–579. PubMed

Porter JR. The role of lymphadenectomy for renal cell carcinoma: are we any closer to an answer? Eur Urol 2017; 17:568–569. PubMed

Capitanio U, Leibovich BC. The rationale and the role of lymph node dissection in renal cell carcinoma. World J Urol 2017; 35:497–506. PubMed

Gershman B, Bukavina L, Chen Z, et al. . The association of robot-assisted versus pure laparoscopic radical nephrectomy with perioperative outcomes and hospital costs. Eur Urol Focus 2020; 6:305–312. PubMed

Crocerossa F, Carbonara U, Cantiello F, et al. . Robot-assisted radical nephrectomy: a systematic review and meta-analysis of comparative studies. Eur Urol 2021; 80:428–439. PubMed

Abaza R, Lowe G. Feasibility and adequacy of robot-assisted lymphadenectomy for renal-cell carcinoma. J Endourol 2011; 25:1155–1159. PubMed

Rose KM, Navaratnam AK, Faraj KS, et al. . Comparison of open and robot assisted radical nephrectomy with level I and II inferior vena cava tumor thrombus: the Mayo clinic experience. Urology 2020; 136:152–157. PubMed

Helmers MR, Ball MW, Gorin MA, et al. . Robotic versus laparoscopic radical nephrectomy: comparative analysis and cost considerations. Can J Urol 2016; 23:8435–8440. PubMed

Golijanin B, Pereira J, Mueller-Leonhard C, et al. . The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urol Oncol 2019; 37:932–940. PubMed

Zareba P, Russo P. The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. Urol Oncol 2019; 37:302.e1–302.e6. PubMed PMC

Yang DY, Potretzke TA, Miest TS, et al. . Timing and distribution of early renal cell carcinoma recurrences stratified by pathological nodal status in M0 patients at the time of nephrectomy. Int J Urol 2020; 27:618–622. PubMed

Srivastava A, Rivera-Núñez Z, Kim S, et al. . Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: evidence in support of expanding the definition of stage IV kidney cancer. Cancer 2020; 126:2991–3001. PubMed

Han J, Li Q, Li P, et al. . Reassessment of american joint committee on cancer staging for stage III renal cell carcinoma with nodal involvement: propensity score matched analyses of a large population-based study. Front Oncol 2020; 10:1–12. PubMed PMC

Demir T, Aliyev A, Beşiroğlu M, et al. . Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma? Curr Probl Cancer 2021; 45:1–9. PubMed

Motzer RJ, Ravaud A, Patard JJ, et al. . Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol 2018; 73:62–68. PubMed PMC

Massari F, Di Nunno V, Mollica V, et al. . Adjuvant tyrosine kinase inhibitors in treatment of renal cell carcinoma: a meta-analysis of available clinical trials. Clin Genitourin Cancer 2019; 17:e339–e344. PubMed

Chakiryan NH, Acevedo AM, Garzotto MA, et al. . Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma. Urol Oncol 2020; 38:604.e1–604.e7. PubMed

Pal SK, Uzzo R, Karam JA, et al. . Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2022; 400:1103–1116. PubMed

Yanagisawa T, Schmidinger M, Kawada T, et al. . Radical nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma. Eur Urol focus 2023; S2 2405-4569:00036-6. PubMed